Siemens Healthineers

Join team

Raising money for Cure Leukaemia

£8,581

raised of £4,500 target

by 260 supporters

London 2 Paris · 6 June 2024 to 10 June 2024 ·

London 2 Paris 2024

Campaign by Cure Leukaemia (RCN 1100154)

Cure Leukaemia's London 2 Paris returns in 2024 for the best four days you can possibly spend on a bike!

Story

Team members (6)

Join team

Robert Dove
£2,582 of £1,500
Hettie Knox
£2,120 of £1,500
Neil Wakefield
£1,770 of £1,500
Siemens Healthineers GBI CSR Committee
Siemens hasn't set a target
£1,043
Conor McGreevy
£600 of £1,500

Help Siemens Healthineers GBI CSR Committee's team

Sharing this page with your friends could help raise up to 3x more in donations

Email

LinkedIn

You can also help by sharing this link on:

260 donations

Great Aunty Kathy
6 months ago
Well done me duck! I am very proud of you xxx
£20.00
Rob Perry
8 months ago
Sorry it’s a late one! Congratulations Rob on an amazing feat. Hope to catch up for a bike ride sometime soon 👍
£20.00 + £5.00 Gift Aid
Siemens Healthineers GBI CSR Committee
8 months ago
Congratulations on completing the ride, Neil! On behalf of Siemens Healthineers, match funding donation for our charity of choice, Cure Leukaemia
£500.00
Siemens Healthineers GBI CSR Committee
8 months ago
Congratulations on completing the ride, Rob. On behalf of Siemens Healthineers, match fund donation for our charity of choice, Cure Leukaemia
£500.00
Siemens Healthineers GBI CSR Committee
8 months ago
Congratulations on completing the ride, Conor! On behalf of Siemens Healthineers, we are delighted to match fund towards our charity of choice, Cure Leukaemia
£500.00

About the campaign

London 2 Paris 2024

Campaign by Cure Leukaemia

Cure Leukaemia's London 2 Paris returns in 2024 for the best four days you can possibly spend on a bike!

About the charity

Cure Leukaemia

Verified by JustGiving

RCN 1100154

www.cureleukaemia.co.uk

With a new blood cancer diagnosis every 27 seconds worldwide, Cure Leukaemia funds research nurses at UK blood cancer centres, giving patients access to treatments through clinical trials. This support drives global significant advancements in blood cancer, impacting those affected by the disease.